Dr William Franklin Winecoff Iii, MD | |
6825 16th St Nw, Washington, DC 20306-0003 | |
(202) 782-2762 | |
(202) 782-3056 |
Full Name | Dr William Franklin Winecoff Iii |
---|---|
Gender | Male |
Speciality | Pathology |
Experience | 48 Years |
Location | 6825 16th St Nw, Washington, District Of Columbia |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1295719433 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207ZP0102X | Pathology - Anatomic Pathology & Clinical Pathology | 18975 (Georgia) | Primary |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
Anne Arundel Gastroenterology Associates, P.a. | 1254337850 | 19 |
Gastroenterology Specialists Of Frederick, P.a. | 8325013907 | 3 |
News Archive
There is no amount, pattern or timing of alcohol use during pregnancy proven safe for a developing fetus. Repeat: there is no amount, pattern or timing of alcohol use during pregnancy proven safe for a developing fetus.
Past randomized clinical trials have shown that non-steroidal anti-inflammatory drugs (NSAIDs), including naproxen, can reduce the risk of colon cancer and precancerous polyps in humans. Now, researchers at Fox Chase Cancer Center have found that an investigational form of naproxen, called nitric oxide-donating naproxen (NO-naproxen), can block one of the earliest molecular changes that lead to colorectal cancer development while also reducing gastrointestinal toxicity, a relatively common side effect associated with NSAIDs.
VION PHARMACEUTICALS, INC., announced today that the U.S. Food and Drug Administration ("FDA") had responded to its Special Protocol Assessment ("SPA") request to evaluate the Phase III randomized trial HOVON AML 92 sponsored by the Dutch-Belgian Cooperative Group for Hematology Oncology ("HOVON") of its lead product Onrigin(TM).
Recent research on Parkinson's disease has focused on the gut-brain connection, examining patients' gut bacteria, and even how severing the vagus nerve connecting the stomach and brain might protect some people from the debilitating disease.
Being moderately overweight or obese appears to increase the risk for developing coronary heart disease events independent of traditional cardiovascular risk factors, according to a meta-analysis of previously published studies in the September 10 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.
› Verified 7 days ago
Entity Name | Gastroenterology Specialists Of Frederick, P.a. |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1427012053 PECOS PAC ID: 8325013907 Enrollment ID: O20040827000369 |
News Archive
There is no amount, pattern or timing of alcohol use during pregnancy proven safe for a developing fetus. Repeat: there is no amount, pattern or timing of alcohol use during pregnancy proven safe for a developing fetus.
Past randomized clinical trials have shown that non-steroidal anti-inflammatory drugs (NSAIDs), including naproxen, can reduce the risk of colon cancer and precancerous polyps in humans. Now, researchers at Fox Chase Cancer Center have found that an investigational form of naproxen, called nitric oxide-donating naproxen (NO-naproxen), can block one of the earliest molecular changes that lead to colorectal cancer development while also reducing gastrointestinal toxicity, a relatively common side effect associated with NSAIDs.
VION PHARMACEUTICALS, INC., announced today that the U.S. Food and Drug Administration ("FDA") had responded to its Special Protocol Assessment ("SPA") request to evaluate the Phase III randomized trial HOVON AML 92 sponsored by the Dutch-Belgian Cooperative Group for Hematology Oncology ("HOVON") of its lead product Onrigin(TM).
Recent research on Parkinson's disease has focused on the gut-brain connection, examining patients' gut bacteria, and even how severing the vagus nerve connecting the stomach and brain might protect some people from the debilitating disease.
Being moderately overweight or obese appears to increase the risk for developing coronary heart disease events independent of traditional cardiovascular risk factors, according to a meta-analysis of previously published studies in the September 10 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.
› Verified 7 days ago
Entity Name | Anne Arundel Gastroenterology Associates, P.a. |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1245258466 PECOS PAC ID: 1254337850 Enrollment ID: O20061004000317 |
News Archive
There is no amount, pattern or timing of alcohol use during pregnancy proven safe for a developing fetus. Repeat: there is no amount, pattern or timing of alcohol use during pregnancy proven safe for a developing fetus.
Past randomized clinical trials have shown that non-steroidal anti-inflammatory drugs (NSAIDs), including naproxen, can reduce the risk of colon cancer and precancerous polyps in humans. Now, researchers at Fox Chase Cancer Center have found that an investigational form of naproxen, called nitric oxide-donating naproxen (NO-naproxen), can block one of the earliest molecular changes that lead to colorectal cancer development while also reducing gastrointestinal toxicity, a relatively common side effect associated with NSAIDs.
VION PHARMACEUTICALS, INC., announced today that the U.S. Food and Drug Administration ("FDA") had responded to its Special Protocol Assessment ("SPA") request to evaluate the Phase III randomized trial HOVON AML 92 sponsored by the Dutch-Belgian Cooperative Group for Hematology Oncology ("HOVON") of its lead product Onrigin(TM).
Recent research on Parkinson's disease has focused on the gut-brain connection, examining patients' gut bacteria, and even how severing the vagus nerve connecting the stomach and brain might protect some people from the debilitating disease.
Being moderately overweight or obese appears to increase the risk for developing coronary heart disease events independent of traditional cardiovascular risk factors, according to a meta-analysis of previously published studies in the September 10 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.
› Verified 7 days ago
Mailing Address | Practice Location Address |
---|---|
Dr William Franklin Winecoff Iii, MD 14416 Ashleigh Greene Rd, Boyds, MD 20841-4377 Ph: (301) 972-9463 | Dr William Franklin Winecoff Iii, MD 6825 16th St Nw, Washington, DC 20306-0003 Ph: (202) 782-2762 |
News Archive
There is no amount, pattern or timing of alcohol use during pregnancy proven safe for a developing fetus. Repeat: there is no amount, pattern or timing of alcohol use during pregnancy proven safe for a developing fetus.
Past randomized clinical trials have shown that non-steroidal anti-inflammatory drugs (NSAIDs), including naproxen, can reduce the risk of colon cancer and precancerous polyps in humans. Now, researchers at Fox Chase Cancer Center have found that an investigational form of naproxen, called nitric oxide-donating naproxen (NO-naproxen), can block one of the earliest molecular changes that lead to colorectal cancer development while also reducing gastrointestinal toxicity, a relatively common side effect associated with NSAIDs.
VION PHARMACEUTICALS, INC., announced today that the U.S. Food and Drug Administration ("FDA") had responded to its Special Protocol Assessment ("SPA") request to evaluate the Phase III randomized trial HOVON AML 92 sponsored by the Dutch-Belgian Cooperative Group for Hematology Oncology ("HOVON") of its lead product Onrigin(TM).
Recent research on Parkinson's disease has focused on the gut-brain connection, examining patients' gut bacteria, and even how severing the vagus nerve connecting the stomach and brain might protect some people from the debilitating disease.
Being moderately overweight or obese appears to increase the risk for developing coronary heart disease events independent of traditional cardiovascular risk factors, according to a meta-analysis of previously published studies in the September 10 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.
› Verified 7 days ago
Dr. Vani Padmanabha, MD Pathology Medicare: Not Enrolled in Medicare Practice Location: 1150 Varnum St Ne, Pathology Department, Washington, DC 20017 Phone: 202-269-7272 | |
Ernest E Lack, MD Pathology Medicare: Not Enrolled in Medicare Practice Location: 110 Irving St Nw, Washington, DC 20010 Phone: 202-877-6190 Fax: 202-877-3820 | |
Andrea L Richardson, MD PHD Pathology Medicare: Accepting Medicare Assignments Practice Location: 5255 Loughboro Rd Nw, Washington, DC 20016 Phone: 202-537-4455 Fax: 202-537-4466 | |
Dr. Isabell Am Sesterhenn, M.D. Pathology Medicare: Not Enrolled in Medicare Practice Location: 6825 16th St Nw, Washington, DC 20306 Phone: 202-782-2756 Fax: 202-782-3056 | |
Christopher Keith Burris, M.D. Pathology Medicare: Accepting Medicare Assignments Practice Location: 810 Potomac Ave Se, Washington, DC 20003 Phone: 202-878-6588 Fax: 202-878-6564 | |
Rafiq Shahid, MD Pathology Medicare: Medicare Enrolled Practice Location: 2300 M St Nw, Washington, DC 20037 Phone: 202-677-6600 Fax: 202-677-6601 | |
Dr. Luigi Kuo Feng Rao, M.D., M.S. Pathology Medicare: Medicare Enrolled Practice Location: 2 Walter Reed Amc Department, 6900 Georgia Avenue, Nw, Washington, DC 20307 Phone: 202-782-1017 Fax: 202-782-3217 |